Correction to: Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products.

Selen, Arzu; Müllertz, Anette; Kesisoglou, Filippos; Ho, Rodney J Y; Cook, Jack A; Dickinson, Paul A; Flanagan, Talia

Selen, Arzu; Müllertz, Anette; Kesisoglou, Filippos; Ho, Rodney J Y; Cook, Jack A; Dickinson, Paul A; Flanagan, Talia.

Afiliação

Selen A; US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, 10903 New Hampshire Ave., Silver Spring, MD, 20993, USA. Arzu.Selen@fda.hhs.gov.
Müllertz A; Bioneer: FARMA, Department of Pharmacy, University of Copenhagen, 2100, Copenhagen, Denmark.
Kesisoglou F; Biopharmaceutics, Pharmaceutical Sciences and Clinical Supply, Merck & Co, Inc., West Point, PA, 19486, USA.
Ho RJY; University of Washington, Seattle, WA, 98195, USA.
Cook JA; Clinical Pharmacology Department, Global Product Development, Pfizer, Inc., Groton, CT, 06340, USA.
Dickinson PA; Seda Pharmaceutical Development Services, Alderley Park, Alderley Edge, Cheshire, SK10 4TG, UK.
Flanagan T; UCB Pharma S.A., Avenue de l'Industrie, 1420, Braine - l'Alleud, Belgium.

AAPS J ; 23(1): 7, 2020 Dec 03.

Article em En | MEDLINE | ID: mdl-33270171

ABSTRACT

ABSTRACT

A Correction to this paper has been published https//doi.org/10.1208/s12248-020-00534-0.

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: AAPS J Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google